NurExone Biologic Management
Management criteria checks 2/4
NurExone Biologic's CEO is Lior Shaltiel, appointed in Jun 2022, has a tenure of 2.42 years. total yearly compensation is $214.16K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 0.58% of the company’s shares, worth CA$340.00K. The average tenure of the management team and the board of directors is 0.6 years and 2.4 years respectively.
Key information
Lior Shaltiel
Chief executive officer
US$214.2k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 2.4yrs |
| CEO ownership | 0.6% |
| Management average tenure | less than a year |
| Board average tenure | 2.4yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$4m |
| Mar 31 2024 | n/a | n/a | -US$4m |
| Dec 31 2023 | US$214k | US$214k | -US$4m |
| Sep 30 2023 | n/a | n/a | -US$4m |
| Jun 30 2023 | n/a | n/a | -US$4m |
| Mar 31 2023 | n/a | n/a | -US$7m |
| Dec 31 2022 | US$296k | US$246k | -US$8m |
Compensation vs Market: Lior's total compensation ($USD214.16K) is about average for companies of similar size in the Canadian market ($USD170.32K).
Compensation vs Earnings: Lior's compensation has been consistent with company performance over the past year.
CEO
Lior Shaltiel
2.4yrs
Tenure
US$214,160
Compensation
Dr. Lior Shaltiel, Ph D., is the Chief Executive Officer and Director of NurExone Biologic Inc., since June 15, 2022. Dr. Shaltiel is an entrepreneur and an awarded scientist with extensive multidisciplina...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 2.4yrs | US$69.53k | 4.95% CA$ 2.9m | |
| CEO & Director | 2.4yrs | US$214.16k | 0.58% CA$ 340.0k | |
| CFO, Financial Director & Secretary | 2.4yrs | US$214.58k | 0.58% CA$ 340.0k | |
| Co-Founder & Business Development Manager | no data | no data | no data | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Head of the neurosurgery department at Shiba & Member of Scientific Advisory Board | less than a year | no data | no data | |
| Head of CMC | less than a year | no data | no data | |
| Head of Bioprocess Development | less than a year | no data | no data | |
| Head of Scientific Collaboration & External Partnerships | less than a year | no data | no data |
0.6yrs
Average Tenure
Experienced Management: NRX's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 2.4yrs | US$69.53k | 4.95% CA$ 2.9m | |
| CEO & Director | 2.4yrs | US$214.16k | 0.58% CA$ 340.0k | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Head of the neurosurgery department at Shiba & Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 1.1yrs | no data | no data | |
| Independent Director | 13.4yrs | US$32.35k | 0.36% CA$ 215.3k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | 2.4yrs | US$10.64k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 1.3yrs | US$4.22k | no data |
2.4yrs
Average Tenure
68yo
Average Age
Experienced Board: NRX's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.